MedTrace Logo

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

NCT05669625 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12440

Last updated 2023-06-18

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

Conditions

  • Varicella

Interventions

BIOLOGICAL

Investigational live attenuated varicella vaccine

0.5 ml/vial

BIOLOGICAL

Placebo of live attenuated varicella vaccine

0.5 ml/vial

Sponsors & Collaborators

  • Beijing Institute of Biological Products Co Ltd.

    collaborator INDUSTRY

  • Jiangsu Province Center for Disease Control and Prevention

    collaborator UNKNOWN

  • China National Biotec Group Company Limited

    lead INDUSTRY

Principal Investigators

  • Hongxing Pan · Jiangsu Province Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-26
Primary Completion
2024-04-14
Completion
2026-09-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669625 on ClinicalTrials.gov